The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health, recently announced that an Ebola vaccine study has made a milestone achievement by enrolling 1,500 planned participants in the Ebola vaccine clinical trial Phase 2, also known as PREVAIL (Partnership for Research on Ebola Vaccines in Liberia).
Last fall, the Liberian Ministry of Health invited NIAID to partner for clinical research to develop vaccines and treatments for the Ebola virus. All of these vaccines and treatments are required to meet the highest safety, medical and ethical standards.
The study, which is a result of a partnership between NIAID and the Liberian Ministry of Health, began in Monrovia, Liberia, on February 2. The purpose of the trial is to determine the safety and effectiveness of two experimental vaccines, called cAd3-EBOZ and VSV-ZEBOV, which are designed to prevent infections from the Ebola virus.
The length and scale of the Ebola outbreak that occurred in West Africa is remarkable: more than 10,000 people died during the outbreak. Thanks to efforts from volunteers and health workers, the outbreak has finally started to be maintained.
Despite the most recent significant achievements in containing the Ebola virus, researchers have yet to develop a licensed, effective Ebola vaccine that will protect people against future outbreaks.
Source: Vaccine News daily